BioStem Technologies, Inc.
Research BioStem Technologies, Inc. (BSEM) on Bullrun: market cap USD 29.23M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBSEM
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 29.23M
- Financial periodQ2 2026
- RevenueUSD 7.90M
- Net income-USD 8.97M
- Gross margin61.3%
Valuation Snapshot
latest market cap is USD 29.23M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | USD 301.83M | USD 31.88M | USD 24.05M | 95.4% | 1.47 | USD 22.83M | USD 4.39M | USD 40.88M |
| FY2023 | USD 16.69M | -USD 8.48M | -USD 3.71M | 92.4% | -0.62 | USD 239.41K | USD 4.72M | -USD 1.34M |
| FY2022 | USD 6.88M | -USD 7.19M | -USD 165.91K | 87.2% | -0.63 | USD 772.14K | USD 5.09M | -USD 4.08M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-20 | USD 29.23M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 64.04M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 230.35M | 9.6 | n/a | n/a |
| 2023 | 2023-12-29 | USD 76.77M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 36.25M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 10.13M | n/a | n/a | n/a |
About BioStem Technologies, Inc.
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a human connective tissue matrix compromised of amniotic tissue intended for wound covering; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BioStem Technologies, Inc.'s market cap?
BioStem Technologies, Inc.'s market capitalization is USD 29.23M.
What does BioStem Technologies, Inc. do?
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.